Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Share-based Compensation (2017 - 2025)

Cue Biopharma's Share-based Compensation history spans 9 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 3.16% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $5.7 million, down 22.57%, while the annual FY2024 figure was $6.8 million, 16.31% down from the prior year.
  • Share-based Compensation for Q3 2025 was $1.5 million at Cue Biopharma, up from $1.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.3 million in Q3 2021 and bottomed at $1.3 million in Q2 2025.
  • The 5-year median for Share-based Compensation is $2.1 million (2022), against an average of $2.1 million.
  • The largest annual shift saw Share-based Compensation skyrocketed 30.36% in 2021 before it plummeted 36.51% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $3.0 million in 2021, then dropped by 29.0% to $2.1 million in 2022, then dropped by 1.89% to $2.1 million in 2023, then fell by 24.61% to $1.6 million in 2024, then fell by 1.86% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Share-based Compensation are $1.5 million (Q3 2025), $1.3 million (Q2 2025), and $1.3 million (Q1 2025).